Preventing low platelets during lung cancer treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called Hetrombopag to see if it can prevent low platelet counts in people with advanced lung cancer who are receiving certain types of chemotherapy. The goal is to help keep platelet levels safe so you can continue your cancer treatment without delays or dose reductions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with advanced lung cancer that has spread to other parts of the body.
- You are about to start or are already on a platinum- or gemcitabine-based chemotherapy cycle that lasts 21 days.
- During a previous cycle of this same chemotherapy, your platelet level dropped below 75 billion per liter.
- Your current platelet level is between 100 and 200 billion per liter.
- You have a good daily activity level (ECOG score 0-2), meaning you are up and about, not bedridden.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
This study tests a medication called eltrombopag to help prevent dangerously low platelet counts (blood cells that help clotting) in breast cancer patients receiving chemotherapy. Low platelets can cause bleeding problems, and this drug may help keep your counts safer during treatment.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This trial tests if Hetrombopag can prevent low blood platelets caused by gemcitabine and cisplatin chemotherapy for nasopharyngeal carcinoma. It may help patients who had low platelets in a previous chemo cycle.
This study tests if a combination of two medications, hetrombopag (a pill) and rhTPO (an injection), can safely raise very low platelet counts in people with solid tumors caused by their cancer treatments. If you have low platelets due to chemo, radiation, or other therapies, this may offer a new option.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.